Publications

Griggs, Jennifer J., Eva Culakova, Melony E. S. Sorbero, Michelle van Ryn, Marek S. Poniewierski, Debra A. Wolff, Jeffrey Crawford, David C. Dale, and Gary H. Lyman. “Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy..” J Clin Oncol 25, no. 3 (January 20, 2007): 277–84. https://doi.org/10.1200/JCO.2006.08.3063.

PMID
17159190
Full Text

Atkins, Michael B., Marc S. Ernstoff, Robert A. Figlin, Keith T. Flaherty, Daniel J. George, William G. Kaelin, Eugene D. Kwon, et al. “Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference..” Clin Cancer Res 13, no. 2 Pt 2 (January 15, 2007): 667s-670s. https://doi.org/10.1158/1078-0432.CCR-06-2231.

PMID
17255291
Full Text

Ready, Neal E., Alan Lipton, Yali Zhu, Paul Statkevich, Emily Frank, Dolores Curtis, and Ronald M. Bukowski. “Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors..” Clin Cancer Res 13, no. 2 Pt 1 (January 15, 2007): 576–83. https://doi.org/10.1158/1078-0432.CCR-06-1262.

PMID
17255280
Full Text

Rosoff, Philip M. “Survivors of childhood cancer - Reply.” New England Journal of Medicine 356, no. 2 (January 11, 2007): 193–94.

Scholars@Duke

Rosoff, P. M. “Dr. Rosoff replies [13].” New England Journal of Medicine 356, no. 2 (January 11, 2007): 193–94.

Scholars@Duke

Oeffinger, K. C., C. A. Sklar, and L. L. Robison. “Dr. Oeffinger and colleagues reply [12].” New England Journal of Medicine 356, no. 2 (January 11, 2007).

Scholars@Duke

Jiao, Li, Manal M. Hassan, Melissa L. Bondy, James L. Abbruzzese, Douglas B. Evans, and Donghui Li. “The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk..” Cancer Lett 245, no. 1–2 (January 8, 2007): 61–68. https://doi.org/10.1016/j.canlet.2005.12.026.

PMID
16458430
Full Text

Dalgleish, A., D. Emerich, M. Glassy, R. J. Kreitman, V. Mironov, M. Morse, and D. Santini. “Editorial Board Focus – February 2007.” Expert Opinion on Biological Therapy 7, no. 2 (January 2, 2007): 157–60. https://doi.org/10.1517/14712598.7.2.157.

Full Text

Pettengell, R., T. Skacel, M. Aapro, U. Duehrsen, V. Easton, and G. Lyman. “Pegfilgrastim provides effective primary prophylaxis against febrile neutropenia in patients with non-Hodgkin's lymphoma undergoing chemotherapy: Initial results from an integrated analysis - The Neulasta Versus Current Neutropenia Management Practice (NEUCUP) Project.” Journal of Supportive Oncology 5, no. 4 SUPPL. 2 (2007): 40–41.

Scholars@Duke

Pages